Accendra Health, Inc. (ACH)
| Market Cap | 214.43M -56.5% |
| Revenue (ttm) | 2.72B -0.0% |
| Net Income | -1.08B |
| EPS | -14.11 |
| Shares Out | 76.58M |
| PE Ratio | n/a |
| Forward PE | 6.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,146,289 |
| Open | 2.960 |
| Previous Close | 2.920 |
| Day's Range | 2.745 - 3.215 |
| 52-Week Range | 1.840 - 7.100 |
| Beta | 1.61 |
| Analysts | Hold |
| Price Target | 4.39 (+56.79%) |
| Earnings Date | Aug 10, 2026 |
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ACH stock is "Hold." The 12-month stock price target is $4.39, which is an increase of 56.79% from the latest price.
News
Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on...
Accendra Health price target lowered to $4.50 from $5 at Citi
Citi lowered the firm’s price target on Accendra Health (ACH) to $4.50 from $5 and keeps a Buy rating on the shares.
Accendra Health files $200M mixed securities shelf
16:19 EDT Accendra Health (ACH) files $200M mixed securities shelf
Accendra Health Registration statement: Registration filing
Accendra Health filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.
Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”...
Accendra Health Announces Early Results of Offers and Consent Solicitations
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the early results of the previously announced offers to exchange (the “Exchange Offers”) any and all o...
Accendra Health Announces Offers and Consent Solicitations
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company's outsta...
Accendra Health Transcript: AGM 2026
The meeting approved all four proposals, including director elections and incentive plan. The company highlighted its transition to a pure play home-based care provider, serving most of the U.S. with a streamlined workforce and strong brand presence.
Accendra Health price target raised to $4.50 from $3 at UBS
UBS raised the firm’s price target on Accendra Health (ACH) to $4.50 from $3 and keeps a Neutral rating on the shares.
Accendra Health price target raised to $6 from $5 at Baird
Baird raised the firm’s price target on Accendra Health (ACH) to $6 from $5 and keeps an Outperform rating on the shares.
Accendra Health price target raised to $5 from $3.25 at Citi
Citi raised the firm’s price target on Accendra Health (ACH) to $5 from $3.25 and keeps a Buy rating on the shares.
Accendra Health Earnings Call Transcript: Q1 2026
First quarter 2026 results met expectations, with revenue down 6.8% year-over-year but up 1% excluding a major payer exit. Gross margins nearly doubled post-divestiture, and a comprehensive balance sheet optimization will reduce debt and extend maturities.
Accendra Health Earnings release: Q1 2026
Accendra Health released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Accendra Health Slides: Q1 2026
Accendra Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Accendra Health Quarterly report: Q1 2026
Accendra Health has published its Q1 2026 quarterly earnings report on May 11, 2026.
Accendra Health reports Q1 EPS (4c) vs. 29c last year
Reports Q1 revenue $627.8M vs. $673.9M last year. “Our first quarter results were aligned with our expectations as we continue our transformation into a pure play home based care company.
Accendra Health backs FY26 guidance for net revenue and adjusted EBITDA
06:38 EDT Accendra Health (ACH) backs FY26 guidance for net revenue and adjusted EBITDA
Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive bala...
Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health price target lowered to $3.25 from $4 at Citi
Citi lowered the firm’s price target on Accendra Health (ACH) to $3.25 from $4 and keeps a Buy rating on the shares.
Accendra Health price target lowered to $3 from $4 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Accendra Health (ACH) to $3 from $4 and keeps a Buy rating on the shares. The firm updated the company’s…
Accendra Health Earnings Call Transcript: Q4 2025
Revenue grew over 3% in 2025 to nearly $2.8B, with strong performance in sleep, ostomy, and urology. 2026 guidance reflects a $300M revenue headwind from a major payer loss, but cost reductions and technology investments are expected to support margins and cash flow.
Accendra Health Annual report: Q4 2025
Accendra Health has published its Q4 2025 annual report on February 19, 2026.